- Home
- VTYX vs VXRT Comparison
VTYX vs VXRT Comparison
Compare VTYX & VXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- VXRT
- Stock Information
- Founded
- VTYX 2018
- VXRT N/A
- Country
- VTYX United States
- VXRT United States
- Employees
- VTYX N/A
- VXRT N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VTYX Health Care
- VXRT Health Care
- Exchange
- VTYX Nasdaq
- VXRT Nasdaq
- Market Cap
- VTYX 184.6M
- VXRT 200.3M
- IPO Year
- VTYX 2021
- VXRT N/A
- Fundamental
- Price
- VTYX $2.30
- VXRT $0.61
- Analyst Decision
- VTYX Buy
- VXRT Strong Buy
- Analyst Count
- VTYX 5
- VXRT 2
- Target Price
- VTYX $8.40
- VXRT $3.00
- AVG Volume (30 Days)
- VTYX 2.3M
- VXRT 1.4M
- Earning Date
- VTYX 11-07-2024
- VXRT 11-13-2024
- Dividend Yield
- VTYX N/A
- VXRT N/A
- EPS Growth
- VTYX N/A
- VXRT N/A
- EPS
- VTYX N/A
- VXRT N/A
- Revenue
- VTYX N/A
- VXRT $16,760,000.00
- Revenue This Year
- VTYX N/A
- VXRT $128.43
- Revenue Next Year
- VTYX N/A
- VXRT N/A
- P/E Ratio
- VTYX N/A
- VXRT N/A
- Revenue Growth
- VTYX N/A
- VXRT 303.27
- 52 Week Low
- VTYX $1.67
- VXRT $0.52
- 52 Week High
- VTYX $11.48
- VXRT $1.54
- Technical
- Relative Strength Index (RSI)
- VTYX 47.68
- VXRT 46.20
- Support Level
- VTYX $2.21
- VXRT $0.53
- Resistance Level
- VTYX $2.54
- VXRT $0.63
- Average True Range (ATR)
- VTYX 0.27
- VXRT 0.05
- MACD
- VTYX -0.05
- VXRT 0.00
- Stochastic Oscillator
- VTYX 8.02
- VXRT 43.69
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.